

RECORDATI: PUBLIC DISCLOSURE

Milan, 8th March 2019 – Please be informed that **the Directors' Reports** approved by the Board of Directors on 28 February 2019 relating to the:

- item 1 (Financial statement's approval and allocation of profit);
- item 3 (Amendment proposal of 2018-2022 Stock Option Plan in favour of the Chief Executive Officer of Recordati S.p.A.); and
- item 4 (Purchase and utilization of treasury stock),

of the agenda of the Ordinary Shareholders' Meeting called for 11 April 2019, are available to the public, as of today, at the Company's registered office and published on the Company's website (www.recordati.it; Section Investors, Shareholders' Meetings) and on the "1info" storage mechanism (www.1info.it).

The Director Report relating to the item 2 (Remuneration policies) of the agenda, together with the Remuneration Report, both also approved by the Board of Directors on 28 February 2019, will be available to the public, by the means indicated above, within the terms prescribed by current laws and regulations.

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,100, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2018 was € 1,352.2 million, operating income was € 442.2 million and net income was € 312.4 million.

For further information:

Recordati website: www.recordati.com

Investor Relations

Marianne Tatschke
(39)0248787393
e-mail: investorelations@recordati.it

Media Relations

Studio Noris Morano
(39)0276004736, (39)0276004745
e-mail: norismorano@studionorismorano.com

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Sede Legale
VIA M. CIVITALI, 1
20148 MILANO, ITALIA
TEL. (39) 0248787.1
FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 i.v.
REG. IMP. MILANO, MONZA, BRIANZA e LODI 00748210150
CODICE FISCALE/P. IVA 00748210150
R.E.A. MILANO 401832

Società Soggetta all'attività di Direzione e Coordinamento di Rossini Luxembourg S.à.r.l